Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
Lineage Cell Therapeutics Inc (LCTX)
AMEXHealth CareBiotechnologySnapshot 2026-11-04
$0.98-4.55%
Close 2026-11-05 · 1-day change
AMEXHealth CareBiotechnologySnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for LCTX yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Advance therapeutic candidates and build cell therapy pipeline | A primary condition in Lineage Cell Therapeutics Inc's published investment case. The stated target is Sustain advancement of cell-based assets pipeline over next 12 months. | Improving | No meaningful progress or setbacks in key therapeutic programs | Qualitative: 2 positive pipeline updates (COR1) vs target of sustained advancement July 2026 news highlights COR1 'Thew and Inject' plan and manufacturing strategy discussions, reinforcing therapeutic pipeline progress. Nov 4, 2026Last status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Nov 5, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Review earningsObserved price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a speculative, development-stage biotech thesis, not an established earnings compounder: the company is loss-making and recent financial performance is weak. Management is advancing therapeutic candidates and manufacturing initiatives, but the thesis remains on watch because results trail the industry cohort.
Valuation is stretched, with a durable premium versus peers and a modest expectations gap. The evidence points to valuation as the main fragility, rather than a combination of expensive valuation, weak fundamentals, and turbulent conditions; confidence in that assessment is low.
Near term, revenue fell from $1.7 million in 2026-Q1 to $1.1 million in 2026-Q2 as collaboration revenue declined, while operating expenses decreased and management reported progress on its candidates and manufacturing work. The next results carry meaningful execution risk: a guidance cut or continued weak sector results could add pressure, while recent earnings events were mostly in line.
Over the multi-year view, the key question is whether OpRegen, COR1, and manufacturing initiatives advance enough to support future partnerships and development progress. Near term, guidance, collaboration revenue, and broader Healthcare sector results are important swing factors; the evidence does not establish their outcomes.
LCTX has development progress and a stronger sector backdrop, but it remains loss-making, weak relative to its cohort, and stretched on valuation. The 1-to-3-year thesis hinges on execution and partnership support, with the next results an important near-term test. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Pursue and maintain partnerships for cell-based assets | The company has partnerships with Roche and WDI to develop cell therapies. | Intact | Loss of key partnerships or no new deals in 2026 | Qualitative condition This condition has no defined numerical measure. Nov 4, 2026Last status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Revenue grows from $1.7M in Q2 to at least $14.6M in 2026 | A primary condition in Lineage Cell Therapeutics Inc's published investment case. The stated target is >= $14.6 million total revenue by 2026-12-31. | Intact | Revenue falls below $14 million in FY26 | Revenue: $1.069M FY2026-Q2; GAAP. Published target: >= $14.6 million total revenue by 2026-12-31. Annual target cannot be compared with a quarterly or TTM observation. Aug 6, 20261,069,000 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-0.09 → $-0.10 · observed estimates
$0.01B → $0.02B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $-0.09 | $10,350,000 | 5 / 5 |
| 2026-07-25 | $-0.09 | $10,350,000 | 5 / 5 |
| 2026-07-26 | $-0.09 | $10,350,000 | 5 / 5 |
| 2026-07-27 | $-0.09 | $10,350,000 | 5 / 5 |
| 2026-07-28 | $-0.09 | $10,350,000 | 5 / 5 |
| 2026-07-29 | $-0.09 | $10,350,000 | 5 / 5 |
| 2026-07-30 | $-0.09 | $18,142,860 | 5 / 7 |
| 2026-07-31 | $-0.09 | $10,350,000 | 5 / 5 |
| 2026-08-01 | $-0.09 | $10,350,000 | 5 / 5 |
| 2026-08-02 | $-0.09 | $18,142,860 | 5 / 7 |
| 2026-08-03 | $-0.09 | $18,142,860 | 5 / 7 |
| 2026-08-04 | $-0.09 | $18,142,860 | 5 / 7 |
| 2026-08-05 | $-0.09 | $18,142,860 | 5 / 7 |
| 2026-08-06 | $-0.09 | $18,142,860 | 5 / 7 |
| 2026-08-07 | $-0.09 | $10,350,000 | 5 / 5 |
| 2026-08-08 | $-0.09 | $10,350,000 | 5 / 5 |
| 2026-08-09 | $-0.09 | $18,142,860 | 5 / 7 |
| 2026-08-10 | $-0.09 | $18,142,860 | 5 / 7 |
| 2026-08-12 | $-0.09 | $10,350,000 | 5 / 5 |
| 2026-08-13 | $-0.10 | $19,640,170 | 5 / 6 |
| 2026-08-14 | $-0.09 | $10,350,000 | 5 / 5 |
| 2026-08-15 | $-0.09 | $10,350,000 | 5 / 5 |
| 2026-08-16 | $-0.09 | $10,350,000 | 5 / 5 |
| 2026-08-17 | $-0.09 | $10,350,000 | 5 / 5 |
| 2026-08-18 | $-0.09 | $10,350,000 | 5 / 5 |
| 2026-08-19 | $-0.09 | $10,350,000 | 5 / 5 |
| 2026-08-20 | $-0.10 | $8,658,200 | 5 / 5 |
| 2026-08-21 | $-0.10 | $8,658,200 | 5 / 5 |
| 2026-08-22 | $-0.10 | $8,658,200 | 5 / 5 |
| 2026-08-23 | $-0.10 | $8,658,200 | 5 / 5 |
| 2026-08-24 | $-0.10 | $8,658,200 | 5 / 5 |
| 2026-08-25 | $-0.10 | $8,658,200 | 5 / 5 |
| 2026-08-26 | $-0.10 | $8,658,200 | 5 / 5 |
| 2026-08-27 | $-0.10 | $8,658,200 | 5 / 5 |
| 2026-08-28 | $-0.10 | $8,658,200 | 5 / 5 |
| 2026-08-29 | $-0.10 | $8,658,200 | 5 / 5 |
| 2026-08-30 | $-0.10 | $8,658,200 | 5 / 5 |
| 2026-08-31 | $-0.10 | $8,658,200 | 5 / 5 |
| 2026-09-01 | $-0.10 | $8,658,200 | 5 / 5 |
| 2026-09-02 | $-0.10 | $8,658,200 | 5 / 5 |
| 2026-09-03 | $-0.10 | $8,658,200 | 5 / 5 |
| 2026-09-04 | $-0.10 | $8,658,200 | 5 / 5 |
| 2026-09-05 | $-0.10 | $8,658,200 | 5 / 5 |
| 2026-09-06 | $-0.10 | $8,658,200 | 5 / 5 |
| 2026-09-07 | $-0.10 | $8,658,200 | 5 / 5 |
| 2026-09-08 | $-0.10 | $8,658,200 | 5 / 5 |
| 2026-09-09 | $-0.10 | $8,658,200 | 5 / 5 |
| 2026-09-10 | $-0.10 | $8,658,200 | 5 / 5 |
| 2026-09-11 | $-0.10 | $8,658,200 | 5 / 5 |
| 2026-09-12 | $-0.10 | $8,658,200 | 5 / 5 |
| 2026-09-13 | $-0.10 | $8,658,200 | 5 / 5 |
| 2026-09-14 | $-0.10 | $8,658,200 | 5 / 5 |
| 2026-09-15 | $-0.10 | $8,658,200 | 5 / 5 |
| 2026-09-16 | $-0.10 | $8,658,200 | 5 / 5 |
| 2026-09-17 | $-0.10 | $8,658,200 | 5 / 5 |
| 2026-09-18 | $-0.10 | $8,658,200 | 5 / 5 |
| 2026-09-19 | $-0.10 | $8,658,200 | 5 / 5 |
| 2026-09-20 | $-0.10 | $8,658,200 | 5 / 5 |
| 2026-09-21 | $-0.10 | $8,658,200 | 5 / 5 |
| 2026-09-22 | $-0.10 | $8,658,200 | 5 / 5 |
| 2026-09-23 | $-0.10 | $8,658,200 | 5 / 5 |
| 2026-09-24 | $-0.10 | $8,658,200 | 5 / 5 |
| 2026-09-25 | $-0.10 | $8,658,200 | 5 / 5 |
| 2026-09-26 | $-0.10 | $19,698,500 | 4 / 5 |
| 2026-09-27 | $-0.10 | $19,698,500 | 4 / 5 |
| 2026-09-28 | $-0.10 | $19,698,500 | 4 / 5 |
| 2026-09-29 | $-0.10 | $19,698,500 | 4 / 5 |
| 2026-09-30 | $-0.10 | $19,698,500 | 4 / 5 |
| 2026-10-01 | $-0.10 | $19,698,500 | 4 / 5 |
| 2026-10-02 | $-0.10 | $19,698,500 | 4 / 5 |
| 2026-10-03 | $-0.10 | $19,698,500 | 4 / 5 |
| 2026-10-04 | $-0.10 | $19,698,500 | 4 / 5 |
| 2026-10-05 | $-0.10 | $19,698,500 | 4 / 5 |
| 2026-10-06 | $-0.10 | $19,698,500 | 4 / 5 |
| 2026-10-07 | $-0.10 | $19,698,500 | 4 / 5 |
| 2026-10-08 | $-0.10 | $19,698,500 | 4 / 5 |
| 2026-10-09 | $-0.10 | $19,698,500 | 4 / 5 |
| 2026-10-10 | $-0.10 | $19,698,500 | 4 / 5 |
| 2026-10-11 | $-0.10 | $19,698,500 | 4 / 5 |
| 2026-10-12 | $-0.10 | $19,698,500 | 4 / 5 |
| 2026-10-13 | $-0.10 | $19,698,500 | 4 / 5 |
| 2026-10-14 | $-0.10 | $19,698,500 | 4 / 5 |
| 2026-10-15 | $-0.10 | $19,698,500 | 4 / 5 |
| 2026-10-16 | $-0.10 | $19,698,500 | 4 / 5 |
| 2026-10-17 | $-0.10 | $19,698,500 | 4 / 5 |
| 2026-10-18 | $-0.10 | $19,698,500 | 4 / 5 |
| 2026-10-19 | $-0.10 | $19,698,500 | 4 / 5 |
| 2026-10-20 | $-0.10 | $19,698,500 | 4 / 5 |
| 2026-10-21 | $-0.10 | $19,698,500 | 4 / 5 |
| 2026-10-22 | $-0.10 | $19,698,500 | 4 / 5 |
| 2026-10-23 | $-0.10 | $19,698,500 | 4 / 5 |
| 2026-10-24 | $-0.10 | $19,698,500 | 4 / 5 |
| 2026-10-25 | $-0.10 | $19,698,500 | 4 / 5 |
| 2026-10-26 | $-0.10 | $19,698,500 | 4 / 5 |
| 2026-10-27 | $-0.10 | $19,698,500 | 4 / 5 |
| 2026-10-28 | $-0.10 | $19,698,500 | 4 / 5 |
| 2026-10-29 | $-0.10 | $19,698,500 | 4 / 5 |
| 2026-10-30 | $-0.10 | $19,698,500 | 4 / 5 |
| 2026-10-31 | $-0.10 | $19,698,500 | 4 / 5 |
| 2026-11-01 | $-0.10 | $19,698,500 | 4 / 5 |
| 2026-11-02 | $-0.10 | $19,698,500 | 4 / 5 |
| 2026-11-03 | $-0.10 | $19,698,500 | 4 / 5 |
| 2026-11-04 | $-0.10 | $19,698,500 | 4 / 5 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 6 Buy / Strong Buy · 1 Hold · 0 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
2 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.